Table 1.
ADCs under development for HER2 BC.
| ADC | Payload | Development Phase in Breast Cancer | NCT Identifier |
|---|---|---|---|
| Vic-trastuzumab duocarmazine | DUBA (DNA-alkylating agent) |
III | TULIP (NCT03262935) |
| ARX788 | AS269 (MT inhibitor) | II | ACE-Breast 03 (NCT04829604) |
| A166 | Duo-5 (MT inhibitor) | I/II | KlusPharma (NCT03602079) |
| BDC-1001 | TLR7/8 agonist | I/II | BBI-20201001 (NCT04278144) |
| ZW49 | N-acyl sulfonamide auristatin (MT inhibitor) |
I | ZWI-ZW49-101 (NCT03821233) |
| Disitamab-vedotin | MMAE (MT inhibitor) |
I/II/III | NCT02881190, NCT03500380, NCT04400695) |
| Zanidatamab zovodotin | Auristatin based (MT inhibitor) |
I | NCT03821233 |
MT: microtubules.